(Diphtheria + pertussis + tetanus) vaccine is under clinical development by Chongqing Zhifei Biological Products and currently in Phase I for Pertussis (Whooping Cough). According to GlobalData, Phase I drugs for Pertussis (Whooping Cough) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Diphtheria + pertussis + tetanus) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Diphtheria + pertussis + tetanus) vaccine overview
Vaccine candidate is under development for the prevention of diphtheria, pertussis, and tetanus. The vaccine consists of a mixture of diphtheria, pertussis, and tetanus antigens. It is administered through intramuscular route.
See Also:
Chongqing Zhifei Biological Products overview
Chongqing Zhifei Biological Products (Zhifei Biological) is a manufacturer of vaccine products. The company products include recombinant novel coronavirus vaccine, recombinant mycobacterium tuberculosis fusion protein, haemophilus influenzae type b conjugate vaccine, meningococcal group A and B polysaccharide vaccine, meningococcal group A and C conjugate vaccine, meningococcal groups A and C haemophilus b conjugate vaccine, haemophilus b conjugate vaccine, mycobacterium vaccae for injection. Its products help in the prevention of invasive meningococcal disease, including meningitis and pneumonia, epidemic cerebrospinal meningitis, Hepatitis A and influenza. The company markets products under the brand names Vaccae, XiFeiBei, Monacon, Mengwick, Ika, M. vaccae, appropriate card, Chi Parkway too, and SmartWide. Zhifei Biological is headquartered in Chongqing, Chongqing, China.
For a complete picture of (Diphtheria + pertussis + tetanus) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
